Previous 10 | Next 10 |
Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month Company Initiates Campaign to Honor Patients and Promote Awareness of Kidney Disease PR Newswire CAMBRIDGE, Mass. , March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq:...
Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference PR Newswire CAMBRIDGE, Mass. , March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people...
Akebia Therapeutics, Inc. (AKBA) Q4 2020 Earnings Conference Call February 25, 2021, 09:00 ET Company Participants Kristen Sheppard - VP, IR John Butler - CEO, President & Director David Spellman - SVP, CFO & Treasurer Conference Call Participants Christopher Raymond - Piper Sandler &...
Shares of Akebia Therapeutics (NASDAQ: AKBA) are falling sharply on Thursday after the company reported mixed fourth-quarter 2020 financial results. At 12:27 p.m. EST, the biopharmaceutical company's stock was down by 17.4%. Akebia Therapeutics' total revenue of $56.7 million fo...
Gainers: Pandion Therapeutics (PAND) +133%.GameStop (GME) +66%.ChromaDex (CDXC) +59%.Dynatronics (DYNT) +57%.Koss (KOSS) +54%.Stereotaxis (STXS) +33%.ASLAN Pharmaceuticals (ASLN) +29%.Socket Mobile (SCKT) +26%.AeroCentury (ACY) +24%.Brookdale Senior Living (BKD) +21%.Loser...
Gainers: Pandion Therapeutics (PAND) +132%, Dynatronics (DYNT) +68%, ChromaDex (CDXC) +30%, ASLAN Pharmaceuticals (ASLN) +28%, Brookdale Senior Living (BKD) +22%.Losers: U.S. Physical Therapy (USPH) -21%, CollPlant Biotechnologies (CLGN)&...
Akebia Therapeutics (AKBA) posted Q4 2020 results that beat analyst expectations on revenue but missed on EPS.Total revenue in the quarter was $56.7M compared to $69.6M in the prior-year period, an 18.5% decline.The company's net loss year over year narrowed to 60 cents per share from 79...
Akebia (AKBA): Q4 GAAP EPS of -$0.60 misses by $0.22.Revenue of $56.7M (-18.5% Y/Y) beats by $8.93M.Shares +1% PM.Press Release For further details see: Akebia EPS misses by $0.22, beats on revenue
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates - Full-year 2020 net product revenue increases to $128.9 million, up 16% from 2019 - Company on track to submit vadadustat NDA by mid-second quarter 2021 - LeAnne M. Zumwalt,...
4 Penny Stocks to Watch as the Market Tries To Recover During the last week of February, the market gods have not been kind to the broader markets. While many penny stocks have escaped unscathed, it seems as though there is a lot of uncertainty right now. On Tuesday, February 23rd, ...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference PR Newswire CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...